Latest News in the pharma Industry

Research & Development

Amgen presents detailed results from Phase III study demonstrating clinical equivalence of biosimilar candidate ABP 501 with adalimumab

Amgen presents detailed results from Phase III study demonstrating clinical equivalence of biosimilar candidate ABP 501 with adalimumab

12 Nov 2015

First completed Phase III study of adalimumab biosimilar in the treatment of patients with moderate-to-severe RA.

Read more 
Regeneron and Sanofi announce new Praluent injection analyses presented at AHA scientific sessions 2015

Regeneron and Sanofi announce new Praluent injection analyses presented at AHA scientific sessions 2015

11 Nov 2015

74% of patients reached their LDL cholesterol goals on 75 mg dose; Of the remaining patients whose dose was adjusted to 150 mg, most achieved their goal.

Read more 
Teva granted Breakthrough Therapy Designation for SD-809 by FDA

Teva granted Breakthrough Therapy Designation for SD-809 by FDA

9 Nov 2015

SD-809 — a much-needed treatment option for the tardive dyskinesia patient population.

Read more 
FDA accepts Amgen's NDA for novel intravenous calcimimetic etelcalcetide

FDA accepts Amgen's NDA for novel intravenous calcimimetic etelcalcetide

9 Nov 2015

If approved, etelcalcetide will be the first calcimimetic agent that can be administered intravenously.

Read more 
Real-world analysis of more than 44,000 patients reinforces safety and effectiveness of Pradaxa in routine clinical care

Real-world analysis of more than 44,000 patients reinforces safety and effectiveness of Pradaxa in routine clinical care

9 Nov 2015

New data show Pradaxa reduced stroke risk and major bleeding compared to warfarin in patients with non-valvular atrial fibrillation.

Read more 
High quality specific ChIP-validated antibodies

High quality specific ChIP-validated antibodies

9 Nov 2015

The company now offeres the first nine antibodies in its Validated Antibody programme which are H3, RNA pol II (S), RNA pol II (S5), H3K9me3, 5mC, AcH3, AcH4, AR and Sin3a

Read more 
Sanofi Pasteur reveals its research on a ”universal” influenza vaccine

Sanofi Pasteur reveals its research on a ”universal” influenza vaccine

9 Nov 2015

The vaccines division of Sanofi presents at the World Vaccine Congress in Spain.

Read more 
Detailed results demonstrate baricitinib superiority to adalimumab in improving signs and symptoms of RA

Detailed results demonstrate baricitinib superiority to adalimumab in improving signs and symptoms of RA

8 Nov 2015

Patient-reported pain, joint stiffness, fatigue and physical function scores significantly improved with baricitinib compared to adalimumab.

Read more 
Alzheon announces efficacy outcomes from two prior Alzheimer’s Phase III studies and initiation of two clinical studies to lead to pivotal trial

Alzheon announces efficacy outcomes from two prior Alzheimer’s Phase III studies and initiation of two clinical studies to lead to pivotal trial

8 Nov 2015

Patients with mild to moderate Alzheimer’s disease and apoe4/4 genotype showed robust and sustained efficacy on cognitive and functional co-primary outcomes over 78 weeks with favorable safety profile.

Read more 
Data on vericiguat, investigational heart failure medicine, to be presented as late-breaking clinical trial at the 2015 AHA Scientific Sessions

Data on vericiguat, investigational heart failure medicine, to be presented as late-breaking clinical trial at the 2015 AHA Scientific Sessions

6 Nov 2015

Vericiguat study in patients with worsening chronic heart failure and reduced ejection fraction.

Read more 
EMA Validates BMS’s type II variation application for Opdivo (nivolumab) in previously treated advanced renal cell carcinoma

EMA Validates BMS’s type II variation application for Opdivo (nivolumab) in previously treated advanced renal cell carcinoma

5 Nov 2015

Overall survival results from CheckMate -025, a landmark Phase 3 study comparing Opdivo versus everolimus in this patient population, serves as basis for application.

Read more 
GSK’s Nucala (mepolizumab) receives approval from FDA

GSK’s Nucala (mepolizumab) receives approval from FDA

6 Nov 2015

First anti-IL5 treatment for adults and adolescents with severe asthma with an eosinophilic phenotype.

Read more